Dr. Samantha McLean,Associate Professor
Information about Dr. Samantha McLean at the University of Bradford.
- School of Pharmacy & Medical Sciences
(Faculty of Life Sciences) - Email:
- s.l.mclean@bradford.ac.uk
- Telephone:
- +44 1274 235809
Biography
Dr Samantha McLean (PhD inNeuropharmacology, University of Bradford, 2010) is a Pharmacologist(University of Leeds, 2006). Sam is appointed as an Associate Professor inPharmacology, Director of Admissions and Marketing for theSchool of Pharmacy and Medical Sciences and Deputy Director of Research atHealth, Society, People and Place in the Faculty of Life Sciences. Sam is a Senior Fellow of theHigher Education Academy, UK (2020). She has experience in leading, developingand accreditation of innovative programmes of study in life sciences atundergraduate and postgraduate levels, including MPharm (GPhC).As Director of Marketing andAdmissions, Sam is managing marketing and recruitment activities across allprogramme levels: MPharm, BSc Clinical Sciences, BSc Pharmaceutical andCosmetic Science and a portfolio of postgraduate MSc and Research taughtprogrammes in the School of Pharmacy and Medical Sciences, Centre forPharmaceutical Engineering Science, and the Institute of Cancer Therapeutics.Her outreach and recruitment agenda spans a variety of projects aimed atimproving access to and widening participation in higher education among homestudents and managing strategic partnerships with internal and externalstakeholders focused on recruitment across international markets. She is an external examinerat Kings College London for the MSc Neuroscience programme, Associate Editor forthe Journal of Neuroscience Research and a member of the Pharmacy andPharmacogenomics Working Group for the Genomic Medicine Service Alliance(Northeast and Yorkshire). As a Trustee and Board memberof the Cellar Trust (a UK-registered mental health charity), Sam is responsiblefor the charity, it’s activities and management supporting people's mentalhealth across the Bradford district, Craven and surrounding areas.
Research
Sam is an expert indeveloping preclinical models of psychiatry and behavioural paradigms to studynovel receptor targets. She has experience in managing research projects withinacademia as well as commercial environments and collaborates with majorpharmaceutical stakeholders focusing on research and development ofantipsychotic and cognitive-enhancing drugs, including their regulatory (FDA)approval.As a Research Fellow atWolfson Centre for Applied Health Research she has experience in applied healthresearch related to mental health and pharmacogenomics. Sam has supervised 5 PhDstudents and led several MSc projects. She has acted as an independent chair,internal and external examiner for several PhD students.Her research has receivedfunding from the Royal Society UK, Alzheimer's Research UK and BradfordDistrict Care NHS Foundation Trust. As deputy research director(Health Society People and Place) she is leading the integration ofinterdisciplinary research themes across the Faculty of Life Sciences,including postgraduate research programmes (PhD, MD). Current research projects include:Exploration of the role of glutamatergicpharmacology and receptor modifications underlying cognitive function in rodentmodels of schizophreniaInvestigation of the importance of the biologicalrhythms and the dopamine system in cognitive dysfunctionValidationof a stem-cell secretome as a therapeutic for neurodegeneration· Implementationof pharmacogenomic testing in mental health settings to inform and improve medicinesoptimisation and personalised prescribingStudieson students’ views about team-based learning and implications of onlineteaching.
Publications
There are 19 publications involving or that are attributed to Dr. Samantha McLean. They are listed as:
- anet/cos (1)
- peer reviewed journal (18)
ANET/COS
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics is the future of prescribing inpsychiatry | 2022 | 309 | Jameson A, Fylan B, Bristow GC, Sagoo GS, Dalton C, Cardno A, Sohal J, McLean SL | 0031-6873 | 10.1211/PJ.2022.1.152215 |
Peer Reviewed Journal
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Effects of subchronic phencyclidine on behaviour of female rats on the elevated plus maze and open field | 2010 | McLean, Samantha L.; Woolley, M.L.; Neill, Joanna C. | |||||||||
| Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats | 2010 | McLean, Samantha L.; Grayson, Ben; Harris, M.; Protheroe, C.; Bate, S.; Woolley, M.L.; Neill, Joanna C. | |||||||||
| A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats | 2008 | McLean, Samantha L.; Beck, J.P.; Woolley, M.L.; Neill, Joanna C. | |||||||||
| Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain | 2011 | Snigdha, S.; Neill, Joanna C.; McLean, Samantha L.; Shemar, G.K.; Cruise, L.; Shahid, M.; Henry, B. | |||||||||
| Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders | 2016 | McLean, Samantha L.; Grayson, Ben; Marsh, S.; Zarroug, S.H.O.; Harte, Michael K.; Neill, Joanna C. | |||||||||
| Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism | 2010 | Neill, Joanna C.; Barnes, Samuel; Cook, Samantha; Grayson, Ben; Idris, Nagi F.; McLean, Samantha L.; Snigdha, S.; Rajagopal, Lakshmi; Harte, Michael K. | |||||||||
| Using haloperidol as an anti-emetic in palliative care: informing practice through evidence from cancer treatment and post-operative contexts | 2013 | McLean, Samantha L.; Blenkinsopp, Alison; Bennett, M.I. | |||||||||
| PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidineinduced cognitive deficit in the attentional set-shifting task in female rats | 2012 | McLean, Samantha L.; Idris, Nagi F.; Grayson, Ben; Gendle, D.F.; Mackie, C.; Lesage, A.S.; Pemberton, D.J.; Neill, Joanna C. | |||||||||
| Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia | 2011 | McLean, Samantha L.; Grayson, Ben; Idris, Nagi F.; Lesage, A.S.; Pemberton, D.J.; Mackie, C.; Neill, Joanna C. | |||||||||
| Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat | 2010 | McLean, Samantha L.; Neill, Joanna C.; Idris, Nagi F.; Marston, H.M.; Wong, E.H.F.; Shahid, M. | |||||||||
| Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat | 2009 | McLean, Samantha L.; Woolley, M.L.; Thomas, D.; Neill, Joanna C. | |||||||||
| D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia | 2009 | McLean, Samantha L.; Idris, Nagi F.; Woolley, M.L.; Neill, Joanna C. | |||||||||
| Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: a preliminary investigation | 2017 | McLean, Samantha L.; Harte, Michael K.; Neill, Joanna C.; Young, A.M.J. | |||||||||
| Stabilized low-n amyloid-ß oligomers induce robust novel object recognition deficits associated with inflammatory, synaptic, and GABAergic dysfunction in the rat | 2018 | Watremez, W.; Jackson, J.; Almari, B.; McLean, Samantha L.; Grayson, B.; Neilla, J.C.; Fischer, N.; Allouche, A.; Koziel, V.; Pillot, T.; Harte, M.K. | |||||||||
| (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) - a novel cortical-preferring catecholamine transmission- and cognition-promoting agent. | 2020 | Journal of Pharmacology and Experimental Therapeutics | 374 | 404 - 419 | Hjorth S; Waters S; Waters N; Tedroff J; Svensson P; Fagerberg A; Edling M; Svanberg B; Ljung E; Gunnergren J; McLean SL; Grayson B; Idris NF; Neill JC; Sonesson C | 1521-0103 | 10.1124/jpet.120.000037 | ||||
| The effect of photoperiod and high fat diet on the cognitive response in photoperiod-sensitive F344 rats. | 2021 | Physiology and Behavior | McLean SL;Yun H;Tedder A;Helfer G; | 1873-507X | 10.1016/j.physbeh.2021.113496 | ||||||
| What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings? | 2021 | Frontiers in Genetics | 12 | Jameson A, Fylan B, Bristow GC, Sagoo GS, Dalton C, Cardno A, Sohal J, McLean SL | https://doi.org/10.3389/fgene.2021.740216 | ||||||
| The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis | 2022 | Frontiers in Physiology | 30 May 2022 | Yun, H: Dumbell, R: Hanna, K: Bowen, J; McLean, SL; Kantamneni, S; Pors, K; Wu, QF; Helfer, G | https://doi.org/10.3389/fphys.2022.897105 |